Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 726.e11-726.e19

  Cuyvers, Elise ^a,b   Bettens, Karolien ^a,b   Philtjens, Stéphanie ^a,b   Van Langenhove, Tim ^a,b,c   Gijselinck, Ilse ^a,b   van der Zee, Julie ^a,b   Engelborghs, Sebastiaan ^b,d   Vandenbulcke, Mathieu ^e   Van Dongen, Jasper ^a,b   Geerts, Nathalie ^a,b   Maes, Githa ^a,b   Mattheijssens, Maria ^a,b   Peeters, Karin ^a,b   Cras, Patrick ^b,c   Vandenberghe, Rik ^e,f   De Deyn, Peter P ^b,d,g   Van Broeckhoven, Christine ^a,b   Cruts, Marc ^a,b   Sleegers, Kristel ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d Hospital Network Antwerp   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; Frontotemporal dementia; IgV set domain; Meta analysis; Rare variants; TREM2

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BELGIAN; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREM2 GENE;

ALZHEIMER'S DISEASE; FRONTOTEMPORAL DEMENTIA; IGV-SET DOMAIN; META-ANALYSIS; RARE VARIANTS; TREM2;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BELGIUM; COHORT STUDIES; FEMALE; FRONTOTEMPORAL DEMENTIA; GENETIC VARIATION; HETEROZYGOTE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC;

EID: 84889590173     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.009     Document Type: Article

References (30)

1. Benitez B.A., Cooper B., Pastor P., Jin S.C., Lorenzo E., Cervantes S., Cruchaga C. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol. Aging 2013, 34, 1711.e15-7.
2. Bettens K., Brouwers N., Van Miegroet H., Gil A., Engelborghs S., De Deyn P.P., Vandenberghe R., Van Broeckhoven C., Sleegers K. Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. J.Alzheimers Dis. 2009, 19:1169-1175.
3. Cacace R., Van Cauwenberghe C., Bettens K., Gijselinck I., van der Zee J., Engelborghs S., Vandenbulcke M., Van Dongen J., Baumer V., Dillen L., Mattheijssens M., Peeters K., Cruts M., Vandenberghe R., De Deyn P.P., Van Broeckhoven C., Sleegers K. C9orf72 G(4)C(2) repeat expansions in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2013, 34, 1712.e1-7.
4. Chouery E., Delague V., Bergougnoux A., Koussa S., Serre J.L., Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum. Mutat. 2008, 29:E194-E204.
5. Colonna M. TREMs in the immune system and beyond. Nat. Rev. Immunol. 2003, 3:445-453.
6. Engelborghs S., Dermaut B., Goeman J., Saerens J., Marien P., Pickut B.A., van den Broeck M., Serneels S., Cruts M., Van Broeckhoven C., De Deyn P.P. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J.Neurol. Neurosurg. Psychiatry 2003, 74:1148-1151.
7. Engelborghs S., Dermaut B., Marien P., Symons A., Vloeberghs E., Maertens K., Somers N., Goeman J., Rademakers R., van den Broeck M., Pickut B., Cruts M., Van Broeckhoven C., De Deyn P.P. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol. Aging 2006, 27:285-292.
8. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J.Psychiatr. Res. 1975, 12:189-198.
9. Gijselinck I., Van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., Engelborghs S., Sieben A., De Jonghe P., Vandenberghe R., Santens P., De Bleecker J., Maes G., Baumer V., Dillen L., Joris G., Cuijt I., Corsmit E., Elinck E., Van Dongen J., Vermeulen S., van den Broeck M., Vaerenberg C., Mattheijssens M., Peeters K., Robberecht W., Cras P., Martin J.J., De Deyn P.P., Cruts M., Van Broeckhoven C. AC9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2011, 11:54-65.
10. Giraldo M., Lopera F., Siniard A.L., Corneveaux J.J., Schrauwen I., Carvajal J., Munoz C., Ramirez-Restrepo M., Gaiteri C., Myers A.J., Caselli R.J., Kosik K.S., Reiman E.M., Huentelman M.J. Variants in triggering receptor expressedon myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol. Aging 2013, 34, 2077.e11-8.
11. Gonzalez Murcia J.D., Schmutz C., Munger C., Perkes A., Gustin A., Peterson M., Ebbert M.T., Norton M.C., Tschanz J.T., Munger R.G., Corcoran C.D., Kauwe J.S. Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiol. Aging 2013, 34, 2889.e11-3.
12. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Lambert J.C., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., St George-Hyslop P., Singleton A., Hardy J. TREM2 variants in Alzheimer's disease. N.Engl. J. Med. 2013, 368:117-127.
13. Guerreiro R.J., Lohmann E., Bras J.M., Gibbs J.R., Rohrer J.D., Gurunlian N., Dursun B., Bilgic B., Hanagasi H., Gurvit H., Emre M., Singleton A., Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. Arch. Neurol. 2012, 70:78-84.
14. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., Rujescu D., Hampel H., Giegling I., Andreassen O.A., Engedal K., Ulstein I., Djurovic S., Ibrahim-Verbaas C., Hofman A., Ikram M.A., van Duijn C.M., Thorsteinsdottir U., Kong A., Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. N.Engl. J. Med. 2013, 368:107-116.
15. Klunemann H.H., Ridha B.H., Magy L., Wherrett J.R., Hemelsoet D.M., Keen R.W., De Bleecker J.L., Rossor M.N., Marienhagen J., Klein H.E., Peltonen L., Paloneva J. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 2005, 64:1502-1507.
16. Lattante S., Le Ber I., Camuzat A., Dayan S., Godard C., Van Bortel I., De Septenville A., Ciura S., Brice A., Kabashi E. TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Neurobiol. Aging 2013, 34. 2443.e1-2.
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
18. Montalbetti L., Ratti M.T., Greco B., Aprile C., Moglia A., Soragna D. Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-Hakola disease heterozygotes. Funct. Neurol. 2005, 20:71-75.
19. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998, 51:1546-1554.
20. Neumann H., Daly M.J. Variant TREM2 as risk factor for Alzheimer's disease. N.Engl. J. Med. 2012, 368:182-184.
21. Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., Tassi I., Takai T., Stanley S.L., Miller M., Shaw A.S., Colonna M. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat. Immunol. 2009, 10:734-743.
22. Paloneva J., Autti T., Raininko R., Partanen J., Salonen O., Puranen M., Hakola P., Haltia M. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurology 2001, 56:1552-1558.
23. Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., Tranebjaerg L., Konttinen Y., Peltonen L. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 2002, 71:656-662.
24. Piccio L., Buonsanti C., Cella M., Tassi I., Schmidt R.E., Fenoglio C., Rinker J., Naismith R.T., Panina-Bordignon P., Passini N., Galimberti D., Scarpini E., Colonna M., Cross A.H. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 2008, 131:3081-3091.
25. Pottier C., Wallon D., Rousseau S., Rovelet-Lecrux A., Richard A.C., Rollin-Sillaire A., Frebourg T., Campion D., Hannequin D. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J.Alzheimers. Dis. 2013, 35:45-49.
26. Rayaprolu S., Mullen B., Baker M., Lynch T., Finger E., Seeley W.W., Hatanpaa K.J., Lomen-Hoerth C., Kertesz A., Bigio E.H., Lippa C., Josephs K.A., Knopman D.S., White C.L., Caselli R., Mackenzie I.R., Miller B.L., Boczarska-Jedynak M., Opala G., Krygowska-Wajs A., Barcikowska M., Younkin S.G., Petersen R.C., Ertekin-Taner N., Uitti R.J., Meschia J.F., Boylan K.B., Boeve B.F., Graff-Radford N.R., Wszolek Z.K., Dickson D.W., Rademakers R., Ross O.A. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 2013, 8:19.
27. Soragna D., Papi L., Ratti M.T., Sestini R., Tupler R., Montalbetti L. An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. J.Neurol. Neurosurg. Psychiatry 2003, 74:825-826.
28. van der Zee J., Pirici D., Van Langenhove T., Engelborghs S., Vandenberghe R., Hoffmann M., Pusswald G., van den Broeck M., Peeters K., Mattheijssens M., Martin J.J., De Deyn P.P., Cruts M., Haubenberger D., Kumar-Singh S., Zimprich A., Van Broeckhoven C. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 2009, 73:626-632.
29. Van Langenhove T., van der Zee J., Gijselinck I., Engelborghs S., Vandenberghe R., Vandenbulcke M., De Bleecker J., Sieben A., Versijpt J., Ivanoiu A., Deryck O., Willems C., Dillen L., Philtjens S., Maes G., Baumer V., van den Broeck M., Mattheijssens M., Peeters K., Martin J.J., Michotte A., Santens P., De Jonghe P., Cras P., De Deyn P.P., Cruts M., Van Broeckhoven C. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTD cohort. JAMA Neurol. 2013, 1-9.
30. Weckx S., Del-Favero J., Rademakers R., Claes L., Cruts M., De Jonghe P., Van Broeckhoven C., De Rijk P. novoSNP, a novel computational tool for sequence variation discovery. Genome Res. 2005, 15:436-442.